[
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK)’s CEO Thinks He’s Got $50 Billion Of New Drugs, Says Jim Cramer",
    "summary": "We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical companies in the world. The firm has benefited from its KEYTRUDA cancer drug over the […]",
    "url": "https://finnhub.io/api/news?id=94c2cbd68767c5b6819a235eae67d9a2fd770bfeaa255d053de6057f970f588a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752345262,
      "headline": "Merck & Co., Inc. (MRK)’s CEO Thinks He’s Got $50 Billion Of New Drugs, Says Jim Cramer",
      "id": 135905863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical companies in the world. The firm has benefited from its KEYTRUDA cancer drug over the […]",
      "url": "https://finnhub.io/api/news?id=94c2cbd68767c5b6819a235eae67d9a2fd770bfeaa255d053de6057f970f588a"
    }
  },
  {
    "ts": null,
    "headline": "Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition",
    "summary": "We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) is one of the stocks Jim Cramer recently discussed. Verona Pharma plc (NASDAQ:VRNA) is a small biotechnology company that focuses on respiratory diseases. Its shares rocketed by 20.6% in July after pharma giant Merck announced that […]",
    "url": "https://finnhub.io/api/news?id=0054a2da94a9ac8b1c74af8c91a89ef0e4998d40af8dcda5743669a9be3e3b14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752345242,
      "headline": "Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition",
      "id": 135903244,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) is one of the stocks Jim Cramer recently discussed. Verona Pharma plc (NASDAQ:VRNA) is a small biotechnology company that focuses on respiratory diseases. Its shares rocketed by 20.6% in July after pharma giant Merck announced that […]",
      "url": "https://finnhub.io/api/news?id=0054a2da94a9ac8b1c74af8c91a89ef0e4998d40af8dcda5743669a9be3e3b14"
    }
  },
  {
    "ts": null,
    "headline": "FDA willing to trade faster drug reviews for lower prices, Bloomberg reports",
    "summary": "FDA Commissioner Marty Makary said the agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the U.S. and other countries, Bloomberg’s Rachel Cohrs Zhang and Sam Hornblower report. Makary said in an interview on Bloomberg Television’s Wall Street Week with David Westin that companies that promise to equalize prices can receive a “national priority review voucher,” which would cut review times to one to two months. The vouchers are part",
    "url": "https://finnhub.io/api/news?id=39b4cc4c3158480c55ef9d63519eb50223d32ca48c2b944773b35b04bc2e6f03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752327363,
      "headline": "FDA willing to trade faster drug reviews for lower prices, Bloomberg reports",
      "id": 135899323,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "FDA Commissioner Marty Makary said the agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the U.S. and other countries, Bloomberg’s Rachel Cohrs Zhang and Sam Hornblower report. Makary said in an interview on Bloomberg Television’s Wall Street Week with David Westin that companies that promise to equalize prices can receive a “national priority review voucher,” which would cut review times to one to two months. The vouchers are part",
      "url": "https://finnhub.io/api/news?id=39b4cc4c3158480c55ef9d63519eb50223d32ca48c2b944773b35b04bc2e6f03"
    }
  }
]